🇺🇸

Broad Market

· daily

Global High-Priority Regulatory Events — May 21, 2026

Today's filing stream (May 21, 2026) reveals a market dominated by three major themes: a landmark consolidation in US REITs with the $69B AvalonBay-Equity Residential merger, a systemic liquidity crisis at Dalrada Technology Group, and a coordinated structural shift by 14 Puerto Rico closed-end funds toward open-end structures. Period-over-period data shows decelerating growth in Indian conglomerates (ITC's revenue +10% YoY but profit only +1%) and extreme revenue contraction in micro-cap energy (Barnwell -29% YoY) and technology (Dalrada -44% YoY). Capital allocation is mixed—aggressive buybacks from Dhanuka Agritech (₹70Cr) and Zydus Lifesciences (₹1,100Cr) contrast with severe cash burn at Dalrada (cash down 52% to $82.6K). A notable pattern of leadership churn emerged with Glimpse Group losing its entire C-suite and Radian Group announcing a CEO transition, while insider activity remains sparse across the stream. The most actionable signals arise from the AvalonBay-EQR merger synergies ($175M gross), Obsidian Therapeutics' promising Phase 2 melanoma data (67% ORR), and the pivot-to-liquidity event across 14 Puerto Rico funds, which may unlock trapped NAV for investors.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 21, 2026

Overnight filings reveal a market bifurcated between aggressive corporate restructuring and operational headwinds. The most significant development is the transformative $1.03B UK asset sale by Sun Communities and the blockbuster AvalonBay-Equity Residential merger, signaling major consolidation in real estate. In earnings, Deere & Co. posted a 5% revenue increase but saw a 2% profit decline, with a sharp 39% drop in its core Production & Precision Agriculture segment, highlighting a mixed industrial outlook. Conversely, e.l.f. Beauty reported a strong 24.6% revenue surge, but net income collapsed 76.5% due to acquisition-related charges, a classic growth-at-a-cost story. A notable cluster of 14 Puerto Rico closed-end funds is pursuing a strategic shift to open-end structures, a potential liquidity catalyst for a previously illiquid market. Insider activity was sparse, but significant shareholder dissent was observed at Rocket Pharmaceuticals, where a director received only 68.2% support. Overall, the data points to a market where balance sheet strength and strategic clarity are rewarded, while companies facing operational decay (DHTI) or dilution risk (Snail, Inc.) are flashing clear warning signs.

27 high priority 23 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 20, 2026

The May 20, 2026, filings reveal a market dominated by strategic capital management and leadership transitions, with a notable undercurrent of financial distress in smaller-cap companies. The most significant capital market activity includes a massive $3.75 billion revolving credit facility for Williams Companies and a $1.375 billion bond issuance for Appalachian Power, signaling robust access to credit for large-cap infrastructure. However, a contrasting theme of financial strain is evident in filings from Golden Minerals, GridAI, and NanoViricides, which are resorting to dilutive equity offerings or debt settlements to manage liquidity. Leadership changes are widespread, with notable CEO departures at Choice Hotels and Clean Harbors, and CFO transitions at Philip Morris, Skillz, and Stryker, suggesting a period of corporate recalibration. While most governance filings (annual meeting results) were routine, the aggregate data points to a bifurcated market where large, well-capitalized firms are optimizing their balance sheets, while smaller entities face existential funding challenges. The overall sentiment is mixed, with a tilt toward cautious optimism in the energy and infrastructure sectors, contrasted by heightened risk in small-cap biotech and mining.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 20, 2026

Today's filings reveal a bifurcated market with strong growth in select industrials and tech (Analog Devices +37% YoY, Dorian LPG +102% YoY, CAVA +32% YoY) contrasting with sharp declines in energy and small-cap names (PrimeEnergy -52.5% net income, Cavitation Technologies -97.5% revenue). The most critical development is the proposed $3.4B transformational merger of Sachem Capital with IRG, which could create a top-10 industrial REIT but carries significant execution risk. Insider activity is notably absent across filings, but capital allocation patterns show a clear preference for debt reduction and buybacks over dividends. The SPAC market shows renewed activity with FutureCorp's $200M IPO filing, while the crypto space sees institutional validation with Morgan Stanley's Solana and Ethereum trust filings. Portfolio-level trends indicate margin compression in consumer-facing names (CAVA, Hasbro) despite revenue growth, while semiconductor and energy shipping sectors demonstrate exceptional operating leverage.

25 high priority 25 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 20, 2026

This intelligence stream reveals a bifurcated market landscape on May 20, 2026, characterized by severe distress in small-cap and micro-cap companies, counterbalanced by robust growth and strategic positioning in larger, more established firms. The most critical developments include a delisting and Chapter 11 bankruptcy filing by Society Pass Inc., alongside a wave of negative earnings surprises and widening losses across a cohort of micro-cap entities (Powerdyne, Renewal Fuels, AppYea, Starfighters Space). Conversely, Analog Devices reported a standout 37% YoY revenue surge, while Apollo Hospitals delivered 18% top-line growth and a 31% EBITDA increase, signaling strong sector-specific demand. A significant trend is the aggressive capital market activity, with multiple SPAC IPOs (FutureCorp Space, Deep Fission) and crypto-asset trust filings (Morgan Stanley for Solana and Ethereum) indicating sustained institutional appetite for thematic and speculative assets. Period-over-period data shows a clear pattern of revenue growth failing to translate to profitability for many growth-stage companies, with operating expenses and non-cash charges eroding bottom lines. Insider activity was notably absent, but capital allocation decisions—such as debt refinancing by Avista Corp. and a $3.75B credit facility for Williams Companies—point to a focus on liquidity management. The overall sentiment is mixed, with high materiality events concentrated in bankruptcy, regulatory actions, and transformative M&A, demanding immediate attention from event-driven investors.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 20, 2026

Overnight filings reveal a bifurcated market, with high-growth tech and LPG shipping surging while traditional energy, real estate, and cash-burning pre-revenue companies deteriorate sharply. Period-over-period data shows Analog Devices leading with 37% revenue growth and 111% EPS expansion, while PrimeEnergy Resources saw a 52.5% net income decline. Insider activity is limited, but restructuring and M&A themes dominate: Select Medical's $16/share buyout, Sachem Capital's $3.4B industrial REIT combination, and Medline's secondary offering signal significant corporate activity. Several micro-cap companies (Cavitation Technologies, Cyber Enviro-Tech, Starfighters Space) face deepening losses and cash crunches. The most actionable themes are the semiconductor recovery (ADI +37% YoY, E20 Capital's $1.07B tech-heavy 13F), the LPG shipping boom (Dorian LPG +102% revenue), and the rising risk of delistings/bankruptcies in distressed micro-caps.

25 high priority 25 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 19, 2026

The May 19, 2026, filing batch reveals a market dominated by capital structure maneuvers, with a clear bifurcation between companies aggressively refinancing or raising debt (Blackstone Mortgage Trust, Sabre Corp, Humana, Southwest Airlines) and those executing strategic M&A or asset sales (Permian Resources, Bank First Corp, GoPro). Insider activity is largely absent from these filings, shifting focus to capital allocation signals: share buybacks (HF Sinclair) and debt-for-equity swaps (Jaguar Health) indicate varied financial health. A significant undercurrent is the wave of shareholder dissent on compensation plans, with several companies (DHI Group, ACCO Brands, Permian Resources) seeing notable 'against' votes, signaling potential governance friction. Forward-looking data points to key catalysts in H2 2026, including Phase 3 readouts for Immunic and pivotal trial enrollment for Nexalin. Overall, the digest points to a market where liquidity management and strategic pivots are paramount, with governance issues emerging as a key risk factor.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 19, 2026

Today's digest reveals a market bifurcated between robust operational growth in select industrials and energy transition plays, and deepening financial distress in several small-cap and micro-cap names. Key themes include a flurry of SPAC activity with both high-profile deals (Einride, Pasqal) and deadline extensions (Plum IV) signaling execution risk, while capital-intensive sectors like cement and data centers show strong volume growth but margin compression. Notable distress signals emerge from Natural Alternatives, Ehave, and TechPrecision, where cash burn, covenant pressure, and related-party financing are acute. Insider activity is limited but notable: GitLab's chair converted all super-voting shares for tax planning, while Home Depot's reaffirmed guidance provides a steady anchor. The day is rich with forward-looking catalysts, including upcoming shareholder votes for the Thermon/CECO merger and Einride's de-SPAC, and a slate of IPOs from foreign issuers with governance risks. Overall, the data suggests a 'barbell' market where high-quality growth and distressed assets coexist, demanding selective positioning.

22 high priority 28 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 19, 2026

The 50 filings from May 19, 2026, reveal a market dominated by capital return events (buybacks/dividends) and significant M&A/de-SPAC activity, but with underlying financial stress in several sectors. A clear theme is the aggressive return of capital to shareholders, with Dhanuka Agritech, Zydus Lifesciences, Welspun Living, and Sarla Performance Fibers announcing buybacks totaling over ₹1,466 crore, signaling strong balance sheets and management confidence. However, this is contrasted by severe financial distress in the US small-cap space, where Natural Alternatives International (NAII) reported a 79% gross profit collapse and TechPrecision Corp secured only a 4-month credit extension, highlighting acute liquidity pressures. The M&A landscape is active but mixed; the Einride/Legato de-SPAC is progressing with a $1.35B valuation and a June 4 vote, while the Permian Basin Royalty Trust deal remains non-binding and the Plum/Controlled Thermal merger faces delays. Insider activity is sparse but notable, with a significant 2.9M share sale by Invesco in Delhivery and a promoter pledge exceeding 50% at Damodar Industries, both bearish signals. Overall, the digest points to a bifurcated market: cash-rich companies are rewarding shareholders, while others face existential refinancing risks and operational deterioration.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 19, 2026

Overnight filings reveal a market bifurcated between robust operational execution in infrastructure and energy transition versus acute distress in small-cap and commodity-exposed names. Home Depot's mixed quarter, with top-line growth but margin compression, sets a cautious tone for consumer spending, while Eagle Materials' record revenue but declining earnings highlights the 'growth without profit' theme in materials. The most significant corporate actions are the $2.2B acquisition of LiveRamp by Publicis and the $1.35B de-SPAC for Einride, signaling strong M&A appetite in data and green tech. However, a cluster of distressed signals—including Novelis's $84M loss from plant fires, TechPrecision's liquidity crunch, and Natural Alternatives' near-zero gross margin—demand immediate risk review. Insider activity is muted, but the conversion of GitLab's chair from supervoting to common stock is a notable governance event. The forward-looking calendar is packed with catalysts, including Thermon's merger vote, Immunic's Phase 3 readout, and multiple SPAC deadlines, offering both event-driven and turnaround opportunities.

22 high priority 28 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 18, 2026

The May 18, 2026, filing cycle reveals a market bifurcated between aggressive capital deployment and acute financial distress. The dominant themes are a wave of equity and debt financing (Akamai, Babcock & Wilcox, Ideal Power, Old Republic) aimed at funding growth and strategic initiatives, contrasted with a high-profile bankruptcy at Bitcoin Depot and a major acquisition of LiveRamp by Publicis. Leadership transitions are widespread, with several companies (Flagstar, NextEra Energy, T. Rowe Price) executing planned successions, while others (Wyndham, CVS Health) face unexpected changes. A notable trend is the use of convertible notes and equity facilities, which provide capital but introduce dilution risks. The healthcare sector shows significant positive activity, with ImmunityBio and Context Therapeutics advancing key pipeline assets. Overall, the data suggests a market where well-capitalized firms are aggressively pursuing growth, while others are restructuring or facing existential challenges.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 18, 2026

Today's filings reveal a bifurcated market: robust M&A activity (LiveRamp acquisition at 30% premium, Artivion's $175M Endospan buy) contrasts with severe distress signals (Bitcoin Depot bankruptcy, Gossamer Bio restructuring). Revenue trends are mixed—LiveRamp (+9% YoY) and Coeur Mining's buyback execution show strength, while iSpecimen (-85% revenue decline) and OLB Group (-28.6%) highlight micro-cap fragility. Insider activity is sparse but notable: Wyndham CEO's health disclosure introduces leadership uncertainty. Capital allocation patterns diverge sharply—CoreCivic's buyback program contrasts with Perma-Fix's dilutive offering. Sector themes include consolidation in building products (QXO/TopBuild), biotech restructuring (Gossamer Bio, Context Therapeutics), and crypto-exposed portfolios (SkyBridge's 97% Bitcoin concentration). The catalyst calendar features LiveRamp shareholder vote, Gossamer Bio exchange offer deadline, and Context Therapeutics' Phase 1 trial initiation.

22 high priority 28 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 18, 2026

The May 18, 2026 filing stream reveals a market bifurcated between aggressive strategic consolidation and acute financial distress. The most dominant theme is a wave of transformative M&A, led by NextEra Energy's $38B+ bid for Dominion Energy and Publicis Groupe's $2.5B acquisition of LiveRamp acquisition signal a high-conviction bet on scale in-sector consolidation and data infrastructure, respectively. However, this bullish activity is sharply contrasted by severe distress signals: Bitcoin Depot has entered bankruptcy, MTNL has disclosed a massive ₹9,339 Cr default, and several micro-cap biote-stage biotechs (ABVC, iSpecimen) are burning cash with no revenue. Period-over-period data shows a stark divergence, with LiveRamp growing revenue 9% YoY and achieving record cash flow, while OLB Group and iSpecimen saw revenues collapse 28.6% and 85.2% YoY, respectively. Insider activity ispersed across these extremes, we see tactical capital deployment via buybacks (CMS Info Systems) and insider-driven moves (TVS Motor's strategic bank stake), alongside a flurry of regulatory and insolvency proceedings in India, indicating a market that is aggressively pricing in both future growth and imminent failure.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 18, 2026

The overnight filing cycle from May 17-18, 2026 reveals a bifurcated landscape: significant M&A activity with premiums (LiveRamp at 30% premium, Artivion $175M acquisition) contrasts with severe financial distress in micro-caps (Bitcoin Depot bankruptcy, iSpecimen 85% revenue decline). Period comparisons show mixed revenue trends—LiveRamp grew 9% YoY while OLB Group fell 28.6% and iSpecimen collapsed 85.2%. Margin compression was evident at LiveRamp (1ppt decline) and Presidio Property Trust (swung to net loss). Equity offerings dominated capital allocation (Perma-Fix, Flux Power, LanzaTech, Estrella), while Coeur Mining executed aggressive buybacks ($69.7M). Forward-looking catalysts include FDA decisions (Outlook Therapeutics May 2026), clinical trial starts (Context Therapeutics Q3 2026), and shareholder votes (CCEP AGM May 28, Gossamer Bio restructuring). Insider trading activity was absent from enriched data, but management changes at Wyndham (CEO health disclosure) and lululemon (CEO transition) add governance angles.

22 high priority 28 medium 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 15, 2026

Across 50 overnight SEC filings for May 14-15, 2026, Q1 2026 10-Qs dominate (25+ filings) revealing mixed results for micro/small caps: 18/25 showed revenue declines averaging -25% YoY (e.g., Volato -96%, FreeCast -35%) but 15/25 narrowed net losses via 20-40% opEx cuts, highlighting cost discipline amid topline weakness. SPACs (e.g., Spring Valley IV/III, Range Capital) maintained stable Trust Accounts (~$230M avg, +0.5-1% QoQ from interest) but flagged massive liabilities like $425M subscription expense. Positive standouts include regulatory clearances (Methode), debt refinancings (TPG RE $500M facilities), and fund gains (Global Macro +11.7% NAV, Nestor +12.4% capital). Neutral themes: Board changes/appointments (James Hardie, Heartland/Globalstar AGMs with strong votes), investor conferences (USA Comp, Kinder Morgan May 19-27), monthly credit metrics (Synchrony/Capital One), and 13F snapshots showing institutional conviction in REITs/tech (Hyundai $48M Claros, Silver Lake $3.6B). Portfolio-level: Margin resilience (12 cos gross profit up YoY despite rev down), cash infusions from IPOs/financings (Rank One +$21M, NeoVolta equity +$21M), but cash burns persist (avg op cash use $1-5M). Implications: Tactical buys in loss-narrowing turnarounds; caution on high-burn SPACs; monitor conferences for guidance.

33 high priority 17 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 14, 2026

Across 50 8-K filings from May 14, 2026, dominant themes include a surge in debt refinancings and issuances totaling over $15B (e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B), signaling robust capital market access amid favorable rates and extending maturities out to 2036. M&A activity highlights consolidation with Apellis Pharmaceuticals fully acquired by Biogen at $41/share + CVR, Iridium's accretive $367M Aireon buy adding $100M annualized revenue, and Presidio's $83M Oklahoma assets deal closing Q3 2026. Leadership transitions are orderly (e.g., RenaissanceRe CFO succession, Selective Insurance CIO retirement), with positive capital returns via CSX's $5B buyback and KeyCorp's $3B program + dividends. Limited period-over-period data shows NeoVolta's nine-month revenue +262% YoY to $13.3M but Q3 flat YoY at $2M and wider $3M net loss, amid residential solar slowdown. Risks cluster in dilutive financings (HyOrc, GridAI) and restructurings (Trinseo's $2B debt cut via Chapter 11), while opportunities emerge in energy acquisitions and SPAC extensions. Sector patterns favor utilities/energy refinancing for balance sheet strength, contrasting mixed sentiment in small-cap tech financings.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 14, 2026

Across 50 SEC filings for May 14, 2026, Q1 2026 results reveal polarized performance: strong revenue growth in niche consumer (Lifeway +37% YoY) and biotech (Intelligent Bio +46% YoY), contrasted by sharp declines in energy (New Fortress -52% YoY revenue) and SPACs facing cash burns despite trust interest income (avg +1000% YoY in 8 SPACs). Debt refinancings (Lumen $2.4B Term B-5) and M&A (Presidio $83M oil/gas acquisition) signal financial maneuvers amid mixed sentiment (28/50 mixed/neutral). SPACs dominate with extensions (GP-Act III to Nov 2026) and deficits widening (avg 10% QoQ in 10 filings), while 13Fs highlight institutional bets on biotech/energy (Rhenman healthcare heavy, Gemsstock energy/gold). Capital allocation leans conservative with buybacks (News Corp $1B program) and dividends steady; forward guidance sparse but Lifeway targets $45-50M EBITDA FY2027. Portfolio trend: 12/25 10-Qs show revenue growth >20% YoY but margins mixed (avg +100bps in winners, -200bps losers), implying selective opportunities in growth outliers amid broader caution.

33 high priority 17 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 14, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus), dominant themes include SPAC lifecycle events (IPOs, extensions, Q1 results with interest-driven net income amid operating losses), Indian corporate actions (buybacks signaling confidence, insolvencies/distress proceedings), and mixed Q1 2026 results for operating companies with revenue declines in media/advertising offset by cash generation or M&A boosts. Period-over-period trends show 6/15 detailed 10-Qs with YoY revenue growth (e.g., Healthcare Triangle +166%, AIxCrypto liquidity via note sale), but 5 with declines (Versant -1.1%, SpringBig -1.3%) and widespread margin pressure or loss widening (Cabaletta +21% net loss); SPACs averaged +500% YoY net income from trust interest but expanding deficits. Critical developments like CSX's $5B buyback authorization, Lumen's $2.4B debt refinancing, Mangalore Refinery's ₹212cr refund win, and Onward/Cybertech buybacks highlight capital returns and deleveraging, while insolvencies (AGS Transact, Sir Shadi Lal scheme) flag distress. Portfolio-level patterns reveal SPAC resilience via extensions (GP-Act III to Nov 2026) but going concern risks (Vernal), and Indian firms splitting between bullish buybacks (avg 2.5% share capital) and negative CIRP. Implications: Tactical opportunities in buybacks/refinancings, caution on biotech/media distress, monitor SPAC combinations.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 14, 2026

Across 50 overnight SEC filings, Q1 2026 results dominate with mixed sentiments: 12/25 10-Qs showed revenue growth averaging +45% YoY (e.g., Lifeway +37%, Intelligent Bio +46%, Karman +51%), but 8 reported declines averaging -35% YoY (e.g., New Fortress -52%, Swarmer -82%), highlighting sector divergence in consumer/health vs energy/tech. SPACs (10 filings) exhibit stability via trust interest income (avg +$1.5M/quarter offsetting operating losses), though cash burns and deficits persist. Debt refinancings (Lumen, Encore upsized €325M notes) and offerings signal financial maneuvers amid positive capital access, while biotech advances (Onconetix publications, Editas 90% LDL-C reduction) provide catalysts. No insider trading reported across filings, but capital allocation trends favor dividends/distributions (Blue Owl +7% payout, News Corp $1B buyback program). Portfolio-level: Margin expansions in 5 firms (Lifeway +360bps, Intelligent Bio +170bps), but compressions in others (Springbig gross -16.8%). Implications: Favor health/consumer outperformers pre-market; monitor SPAC extensions/deadlines for M&A catalysts.

33 high priority 17 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 13, 2026

Across 50 SEC filings from May 13, 2026, dominant themes include strong shareholder approval at annual meetings (e.g., 15+ companies with >90% support for directors/auditors), mixed Q1/FY2026 earnings with biotech/pharma showing robust revenue growth (avg +50% YoY in 5 reporters like Aquestive +66%, Eos +445%) offset by consumer declines (Jack in the Box -4.3% rev YoY, Prestige -4.3%), and heightened M&A activity including Allegiant's $140M synergy acquisition of Sun Country. Capital allocation trends favor shareholder returns (Hanover $700M buyback) and debt optimization (Las Vegas Sands refinancing $1B notes, Tempus $350M convertibles). Executive churn signals caution (HF Sinclair CFO termination, Rent the Runway CEO departure) amid positive appointments and expansions (Applied Opto lease, Venu amphitheater). Period-over-period, margins compressed in 4/8 earnings reporters (avg -200bps, e.g., Jack in the Box 16.4% vs 19.6%), but cash flows improved in 6/10 (Doximity +19% FCF). Portfolio-level, biotech outperforms with trial catalysts, while SPACs extend deadlines (7 filings), pointing to prolonged deal hunts. Market implications: Favor growth biotechs and M&A plays, monitor consumer weakness and governance stability.

50 high priority 50 total filings